Why Enoxaparin is Prescribed During Pregnancy
Enoxaparin (low-molecular-weight heparin) is prescribed during pregnancy primarily to prevent and treat venous thromboembolism (VTE), which is a leading cause of maternal death, and to provide prophylaxis in women with prior VTE or thrombophilia. 1
Primary Indications
Treatment of Acute VTE
- For pregnant women with acute VTE, LMWH (enoxaparin) is strongly recommended over unfractionated heparin 1
- VTE complicates approximately 1.2 per 1000 deliveries but remains a leading cause of maternal morbidity and mortality 1
- Enoxaparin is the therapy of choice because it provides superior efficacy and safety compared to alternatives 2
VTE Prophylaxis Based on History
The decision to use prophylactic enoxaparin depends on the nature of prior VTE:
- Strong recommendation FOR prophylaxis: Women with a history of unprovoked VTE or hormone-associated VTE should receive antepartum anticoagulant prophylaxis 1
- Conditional recommendation AGAINST prophylaxis: Women whose prior VTE was associated with a resolved non-hormonal provoking risk factor (e.g., surgery, trauma) may not need prophylaxis 1
Additional Clinical Scenarios
Enoxaparin is also prescribed for:
- Valvular heart disease with valve replacement, atrial fibrillation, or thrombus (60% of cases in one series) 3
- Thrombophilia (inherited or acquired clotting disorders) 3
- Recurrent pregnancy losses (18% of cases), though evidence remains mixed 3, 4
- Chronic DVT requiring ongoing anticoagulation 3
Mechanisms Beyond Anticoagulation
While anticoagulation is the primary mechanism, enoxaparin may provide additional benefits through:
- Anti-inflammatory effects at the trophoblast-endometrial interface 5
- Immunomodulant properties that may improve placentation 5
- Potential reduction in placenta-related complications (preeclampsia, fetal growth restriction), though data remain unclear 5, 4
Dosing Approach
Either once-daily or twice-daily dosing regimens are acceptable for VTE treatment 1:
- Treatment doses: typically 1 mg/kg subcutaneously once or twice daily 3
- Prophylactic doses: 30-40 mg subcutaneously daily (standard fixed dosing)
- Routine anti-factor Xa monitoring is NOT recommended for most patients 1
When Monitoring May Be Needed
Anti-factor Xa testing should be reserved for specific situations 2:
- Extreme body weights
- Renal impairment
- When dose adjustment decisions are needed
- Not for routine use in stable patients
Safety Profile
Enoxaparin has demonstrated safety and efficacy across multiple studies 3:
- No thromboembolic events in a 3-year tertiary care series of 55 patients 3
- No documented thrombocytopenia or clinical fractures 3
- Increased risk of postpartum hemorrhage requires preparedness with hemorrhage protocols 2
Critical Peripartum Management
Scheduled delivery with prior discontinuation of anticoagulation is suggested 1:
- Allows for safe neuraxial anesthesia (epidural/spinal)
- Reduces bleeding risk at delivery
- Requires coordination between obstetrics, anesthesia, and hematology 2
Common Pitfalls to Avoid
- Do not use warfarin during pregnancy - it crosses the placenta and causes fetal complications
- Do not routinely monitor anti-factor Xa levels - only when clinically indicated 1
- Ensure access to hemorrhage protocols - patients on LMWH have increased PPH risk 2
- Plan delivery timing carefully - anticoagulation must be held for neuraxial anesthesia
- Do not assume all prior VTE requires prophylaxis - assess whether the prior event had a resolved provoking factor 1
Multidisciplinary Coordination Required
Optimal care requires 2:
- Obstetrics/maternal-fetal medicine
- Hematology/thrombosis specialists
- Anesthesiology (for delivery planning)
- Access to imaging for VTE diagnosis (duplex ultrasound, CTPA, MR venography)
- Hemorrhage management capabilities